154 related articles for article (PubMed ID: 30832965)
41. Assessment of Treatment Effects and Long-term Benefits in Immune Checkpoint Inhibitor Trials Using the Flexible Parametric Cure Model: A Systematic Review.
Filleron T; Bachelier M; Mazieres J; Pérol M; Meyer N; Martin E; Mathevet F; Dauxois JY; Porcher R; Delord JP
JAMA Netw Open; 2021 Dec; 4(12):e2139573. PubMed ID: 34932105
[TBL] [Abstract][Full Text] [Related]
42. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes.
Gabani P; Fischer-Valuck BW; Johanns TM; Hernandez-Aya LF; Keller JW; Rich KM; Kim AH; Dunn GP; Robinson CG; Chicoine MR; Huang J; Abraham CD
Radiother Oncol; 2018 Aug; 128(2):266-273. PubMed ID: 29960685
[TBL] [Abstract][Full Text] [Related]
43. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
44. Nivolumab plus ipilimumab in the treatment of advanced melanoma.
Tsai KK; Daud AI
J Hematol Oncol; 2015 Oct; 8():123. PubMed ID: 26518223
[TBL] [Abstract][Full Text] [Related]
45. Applying State-of-the-Art Survival Extrapolation Techniques to the Evaluation of CAR-T Therapies: Evidence from a Systematic Literature Review.
Sussman M; Crivera C; Benner J; Adair N
Adv Ther; 2021 Aug; 38(8):4178-4194. PubMed ID: 34251651
[TBL] [Abstract][Full Text] [Related]
46. Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study.
Russi A; Damuzzo V; Chiumente M; Pigozzo J; Cesca M; Chiarion-Sileni V; Palozzo AC
J Chemother; 2017 Aug; 29(4):245-251. PubMed ID: 28398170
[TBL] [Abstract][Full Text] [Related]
47. Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review.
Kuo JC; Lilly LB; Hogg D
Melanoma Res; 2018 Feb; 28(1):61-64. PubMed ID: 29140833
[TBL] [Abstract][Full Text] [Related]
48. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
49. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma.
Changizzadeh PN; Mukkamalla SKR; Armenio VA
J Immunother Cancer; 2017 Dec; 5(1):97. PubMed ID: 29254501
[TBL] [Abstract][Full Text] [Related]
50. The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK.
Larkin J; Hatswell AJ; Nathan P; Lebmeier M; Lee D
PLoS One; 2015; 10(12):e0145524. PubMed ID: 26700304
[TBL] [Abstract][Full Text] [Related]
51. Ipilimumab. Immunostimulant; more assessment needed.
Prescrire Int; 2012 Jun; 21(128):145-7. PubMed ID: 22822590
[TBL] [Abstract][Full Text] [Related]
52. Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort.
Jung M; Lee J; Kim TM; Lee DH; Kang JH; Oh SY; Lee SJ; Shin SJ
Cancer Res Treat; 2017 Jan; 49(1):44-53. PubMed ID: 27121719
[TBL] [Abstract][Full Text] [Related]
53. SurvInt: a simple tool to obtain precise parametric survival extrapolations.
Gallacher D
BMC Med Inform Decis Mak; 2024 Mar; 24(1):76. PubMed ID: 38486175
[TBL] [Abstract][Full Text] [Related]
54. Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
Spain L; Larkin J
Immunotherapy; 2016 Jun; 8(6):677-9. PubMed ID: 27197536
[No Abstract] [Full Text] [Related]
55. Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials.
Ascierto PA; Long GV
Lancet Oncol; 2016 Aug; 17(8):1037-1039. PubMed ID: 27324281
[No Abstract] [Full Text] [Related]
56. A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities.
Grumberg V; Roze S; Chevalier J; Borrill J; Gaudin AF; Branchoux S
Int J Technol Assess Health Care; 2022 Mar; 38(1):e28. PubMed ID: 35331347
[TBL] [Abstract][Full Text] [Related]
57. Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma.
Failing JJ; Finnes HD; Kottschade LA; Allred JB; Markovic SN
Melanoma Res; 2016 Dec; 26(6):609-615. PubMed ID: 27603551
[TBL] [Abstract][Full Text] [Related]
58. [Acutely induced diabetes mellitus in a 63-year-old female after treatment with ipilimumab for metastatic melanoma].
Jørgensen LB; Yderstræde K
Ugeskr Laeger; 2017 Sep; 179(37):. PubMed ID: 28918779
[TBL] [Abstract][Full Text] [Related]
59. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.
Ascierto PA; Del Vecchio M; Robert C; Mackiewicz A; Chiarion-Sileni V; Arance A; Lebbé C; Bastholt L; Hamid O; Rutkowski P; McNeil C; Garbe C; Loquai C; Dreno B; Thomas L; Grob JJ; Liszkay G; Nyakas M; Gutzmer R; Pikiel J; Grange F; Hoeller C; Ferraresi V; Smylie M; Schadendorf D; Mortier L; Svane IM; Hennicken D; Qureshi A; Maio M
Lancet Oncol; 2017 May; 18(5):611-622. PubMed ID: 28359784
[TBL] [Abstract][Full Text] [Related]
60. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
Martens A; Wistuba-Hamprecht K; Geukes Foppen M; Yuan J; Postow MA; Wong P; Romano E; Khammari A; Dreno B; Capone M; Ascierto PA; Di Giacomo AM; Maio M; Schilling B; Sucker A; Schadendorf D; Hassel JC; Eigentler TK; Martus P; Wolchok JD; Blank C; Pawelec G; Garbe C; Weide B
Clin Cancer Res; 2016 Jun; 22(12):2908-18. PubMed ID: 26787752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]